The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels

  • Emine Çiloğlu
  • Fikret Unal
  • Nese Cetin Dogan
Retinal Disorders



The purpose of this study were to compare the levels of serum cortisol, aldosterone, testosterone, dehydroepiandrosterone (DHEA), and renin hormone between patients with central serous chorioretinopathy (CSC) and a control group, and to investigate whether there was a difference regarding serum hormone levels in patients with acute/chronic CSC.


This prospective study included 30 CSC eyes, 30 fellow eyes, and 32 normal eyes of 32 healthy volunteers who were age and sex matched. The patients were classified as acute or chronic depending on the clinical, fluorescein angiography (FFA), and optical coherence tomography (OCT) findings. Serum cortisol, aldosterone, renin, total testosterone, and DHEA levels were measured. The levels of hormones were compared with the values of the control group. Choroidal thickness and central macular thickness were measured with spectral domain OCT.


Fifteen patients had acute CSC, and 15 patients had chronic CSC. Serum testosterone levels were 357 ± 10.4 ng/ml in the CSC group, and 255.94 ± 7.43 ng/ml in the control group. The difference between them was statistically significant (p < 0.001). The difference between the levels of cortisol, renin, aldosterone, and DHEA was not statistically significant. Serum hormone levels were within the normal range for all patients and were not statistically different between the acute and chronic CSC groups.


According to our results, CSC is related to elevated total testosterone levels. Testosterone may play a role in predisposing males to CSC.


Central serous chorioretinopathy Cortisol Testosterone Aldosterone Renin 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 115:169–173CrossRefPubMedGoogle Scholar
  2. 2.
    Wang M, Munch IC, Hasler PW, Prünte C, Larsen M (2008) Central serous chorioretinopathy. Acta Ophthalmol 86:126–145CrossRefPubMedGoogle Scholar
  3. 3.
    Hussain D, Gass JD (1998) Idiopathic central serous chorioretinopathy. Indian J Ophthalmol 46(3):131–137PubMedGoogle Scholar
  4. 4.
    Gass JDM (1997) Stereoscopic atlas of macular diseases, 4th edn. Mosby, St. Louis, MO, pp 760–763Google Scholar
  5. 5.
    Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D (1994) Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 112(8):1057–1062CrossRefPubMedGoogle Scholar
  6. 6.
    Prünte C, Flammer J (1996) Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 121(1):26–34CrossRefPubMedGoogle Scholar
  7. 7.
    Kim YT, Kang SW, Bai KH (2011) Choroidal thickness in both eyes of patients with unilaterally active central serous chorioretinopathy. Eye (Lond) 25(12):1635–1640CrossRefGoogle Scholar
  8. 8.
    Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S (2004) Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 111:244–249CrossRefPubMedGoogle Scholar
  9. 9.
    Liew G, Quin G, Gillies M, Fraser-Bell S (2013) Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 41:201–214CrossRefPubMedGoogle Scholar
  10. 10.
    Gelber GS, Schatz H (1987) Loss of vision due to central serous chorioretinopathy following psychological stress. Am J Psychiatry 144(1):46–50CrossRefPubMedGoogle Scholar
  11. 11.
    Yannuzzi LA (2012) Type A behavior and central serous chorioretinopathy. Retina 32(Suppl 1):709CrossRefPubMedGoogle Scholar
  12. 12.
    Zakir SM, Shukla M, Simi SU, Ahmad J, Sajid M (2009) Serum cortisol and testosterone levels in idiopathic central serous chorioretinopathy. Indian J Ophthalmol 57(6):419–422CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Garg SP, Dada T, Talwar D, Bidwas NR (1997) Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol 81(11):962–964CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Thoelen AM, Bernasconi PP, Schmid C, Messmer EP (2000) Central serous chorioretinopathy associated with a carcinoma of the adrenal cortex. Retina 20:98–99CrossRefPubMedGoogle Scholar
  15. 15.
    Pastor-Idoate S, Pena D, Herreras JM (2011) Adrenocortical adenoma and central serous chorioretinopathy: a rare association? Case Rep Ophthalmol 2:327–332CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Chalisgaonkar C, Chouhan S, Lakhtakia S et al (2010) Central serous chorioretinopathy and endogenous cortisol: is there an association? Indian J Ophthalmol 58:449–450CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tufan HA, Gencer B, Comez AT (2013) Serum cortisol and testosterone levels in chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 251:677–680CrossRefPubMedGoogle Scholar
  18. 18.
    Zumoff B, Rosenfeld RS, Friedman M, Byers SO, Rosenman RH, Hellman L (1984) Elevated daytime urinary excretion of testesterone glucuronide in men with type A behavior pattern. Psychocom Med 46:223–225CrossRefGoogle Scholar
  19. 19.
    Rocha EM, Wickham LA, da Silveira LA, Krenzer KL, Yu FS, Toda I, Sullivan BD, Sullivan DA (2000) Identification of androgen receptor protein and 5 alpha-reductase mRNA in human ocular tissues. Br J Ophthalmol 84:76–84CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ahad MA, Chua CN, Evans NM (2006) Central serous chorioretinopathy associated with testosterone therapy. Eye (Lond) 20:503–505CrossRefGoogle Scholar
  21. 21.
    Imamura Y, Fujiwara T, Margolis R, Spaide RF (2009) Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 29(10):1469–1473CrossRefPubMedGoogle Scholar
  22. 22.
    Maruko I, Iida T, Sugano Y, Ojima A, Sekiryu T (2011) Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina 31(8):1603–1608CrossRefPubMedGoogle Scholar
  23. 23.
    Lıu T, Dong Y, Zeng DF, Xıe L, Ye J, He XG (2014) Acase of adult-onset Still’s disease presenting with multifocal central serous chorioretinopathy. Eur Rev Med Pharmacol Sci 18:421–425PubMedGoogle Scholar
  24. 24.
    Yang LH, Tian B, Shi XH, Ding N, Zhou D, Wei WB (2012) Changes in choroidal thickness in central serous chorioretinopathy. Zhonghua Yan Ke Za Zhi 48:872–877Google Scholar
  25. 25.
    Watanabe S, Ohtsuki K (1979) Experimental serous chorioretinopathy. Ada Soc Ophthalmol Jpn 83(7):808–817Google Scholar
  26. 26.
    Yoshioka H (1991) The etiology of central serous chorioretinopathy. Ada Soc Ophthalmol Jpn 95(12):1181–1195Google Scholar
  27. 27.
    Zhao M, Célérier I, Bousquet E et al (2012) Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 122(7):2672–2679CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Bonvalet JP (1998) Regulation of sodium transport by steroid hormones. Kidney Int Suppl 65:S49–S56PubMedGoogle Scholar
  29. 29.
    Bouzas EA, Karadımas P, Pournaras CJ (2002) Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 47:431–448CrossRefPubMedGoogle Scholar
  30. 30.
    Gong Q, Sun XH, Yuan ST, Lıu QH (2017) The releation of the serum aldosterone level and central serous chorioretinopathy-a pilot study. Eur Rev Med Pharmacol Sci 21:446–453PubMedGoogle Scholar
  31. 31.
    Homovici R, Rumelt S, Melby J (2003) Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 110:698–703CrossRefGoogle Scholar
  32. 32.
    Grieshaber MC, Staub JJ, Flammer J (2007) The potential role of testosterone in central serous chorioretinopathy. Br J Ophthalmol 91:118–119CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Nudleman E, Witmer MT, Kiss S et al (2014) Central serous chorioretinopathy in patients receiving exogenous testosterone theraphy. Retina 34:2128–2132CrossRefPubMedGoogle Scholar
  34. 34.
    Conway MD, Noble JA, Peyman GA (2016) Central serous chorioretinopathy in postmenopausal women receiving exogenous testosterone. Retin Cases Brief Rep 0:1–5Google Scholar
  35. 35.
    Natung T, Keditsu A (2015) Comparison of serum cortisol and testosterone levels in acute and chronic central serous chorioretinopathy. Korean J Ophthalmol 29(6):382–388CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Islam QU, Hanif MK, Tareen S (2016) Frequency of systemic risk factors in central serous chorioretinopathy. J Coll Physicians Surg Pak 26(8):692–695PubMedGoogle Scholar
  37. 37.
    Turkcu FM, Yuksel H, Yuksel H, Sahin A, Cınar Y, Cingu AK, Sahın M, Caca İ (2014) Serum dehydroepiandrosterone sulphate, total antioxidant capacity and total oxidant status in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 252(1):17–21CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of OphthalmologyAdana City HospitalAdanaTurkey
  2. 2.Adana Şehir HastanesiGöz Hastalıkları KliniğiAdanaTurkey

Personalised recommendations